Meptazinol

Meptazinol

Clinical data
AHFS/Drugs.com	International Drug Names
Dependence liability	Low
Routes of administration	Oral, IM, IV
ATC code	N02AX05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Metabolism	The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours.
Elimination half-life	Half-Life (1.4–4 hours).
Excretion	The drug is rapidly metabolised to the glucuronide, and mostly excreted in the urine.
Identifiers
IUPAC name (RS)-3-(3-ethyl-1-methylazepan-3-yl)phenol
CAS Number	59263-76-2 N
PubChem CID	41049
ChemSpider	37469 Y
UNII	18Y7S5JKZD
KEGG	D08182 Y
ChEMBL	ChEMBL314437 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H23NO
Molar mass	233.34922 g/mol
3D model (JSmol)	Interactive image
SMILES OC1=CC=CC(C2(CCCCN(C2)C)CC)=C1
InChI InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3 Y Key:JLICHNCFTLFZJN-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Meptazinol
Articles
Most recent articles on Meptazinol Most cited articles on Meptazinol Review articles on Meptazinol Articles on Meptazinol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Meptazinol Images of Meptazinol Photos of Meptazinol Podcasts & MP3s on Meptazinol Videos on Meptazinol
Evidence Based Medicine
Cochrane Collaboration on Meptazinol Bandolier on Meptazinol TRIP on Meptazinol
Clinical Trials
Ongoing Trials on Meptazinol at Clinical Trials.gov Trial results on Meptazinol Clinical Trials on Meptazinol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Meptazinol NICE Guidance on Meptazinol NHS PRODIGY Guidance FDA on Meptazinol CDC on Meptazinol
Books
Books on Meptazinol
News
Meptazinol in the news Be alerted to news on Meptazinol News trends on Meptazinol
Commentary
Blogs on Meptazinol
Definitions
Definitions of Meptazinol
Patient Resources / Community
Patient resources on Meptazinol Discussion groups on Meptazinol Patient Handouts on Meptazinol Directions to Hospitals Treating Meptazinol Risk calculators and risk factors for Meptazinol
Healthcare Provider Resources
Symptoms of Meptazinol Causes & Risk Factors for Meptazinol Diagnostic studies for Meptazinol Treatment of Meptazinol
Continuing Medical Education (CME)
CME Programs on Meptazinol
International
Meptazinol en Espanol Meptazinol en Francais
Business
Meptazinol in the Marketplace Patents on Meptazinol
Experimental / Informatics
List of terms related to Meptazinol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s. Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics (childbirth). A partial µ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full µ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.

It does not appear in the US Controlled Substances Act 1970; it may or may not be regulated as an analogue of controlled relatives such as proheptazine (ACSCN 9643)